Brokers Set Expectations for Pfizer’s Q4 Earnings (NYSE:PFE)

Pfizer Inc. (NYSE:PFE) – Analysts at Leerink Partnrs decreased their Q4 2024 earnings per share (EPS) estimates for Pfizer in a research report issued on Tuesday, October 29th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $0.63 per share for the quarter, down from their previous estimate of $0.79. The consensus estimate for Pfizer’s current full-year earnings is $2.95 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2027 earnings at $3.19 EPS.

Other equities research analysts have also issued research reports about the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Sanford C. Bernstein assumed coverage on Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price on the stock. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research report on Wednesday, August 7th. Citigroup started coverage on Pfizer in a research report on Friday, October 25th. They issued a “neutral” rating and a $30.00 price objective on the stock. Finally, Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday. Eight analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.58.

Pfizer Stock Down 0.8 %

Shares of Pfizer stock opened at $28.29 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. Pfizer has a 52-week low of $25.20 and a 52-week high of $31.54. The company’s 50 day moving average price is $29.05 and its 200-day moving average price is $28.56. The stock has a market capitalization of $160.31 billion, a price-to-earnings ratio of 38.23, a P/E/G ratio of 0.90 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.40% and a net margin of 7.07%. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. During the same period last year, the company earned ($0.17) EPS. Pfizer’s revenue for the quarter was up 31.2% compared to the same quarter last year.

Hedge Funds Weigh In On Pfizer

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Olistico Wealth LLC purchased a new position in shares of Pfizer during the second quarter valued at approximately $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter valued at $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer in the 2nd quarter worth $34,000. Finally, ESL Trust Services LLC bought a new stake in shares of Pfizer in the first quarter worth $37,000. 68.36% of the stock is owned by institutional investors.

Insider Activity at Pfizer

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The shares were purchased at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is currently owned by insiders.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.94%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s payout ratio is 227.03%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.